NEW YORK, Feb. 10, 2006 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) announced today that Douglas Abel, president and chief executive officer, will be a panelist for the "Obesity: Advances in Obesity Drugs" Focus Session at the upcoming BIO CEO & Investor Conference in New York City. The Obesity Focus Session will be held on Tuesday, February 14, 2006, at 9:00 am Eastern Time in the Basildon Room of the Waldorf-Astoria, New York City.
The session will highlight new advances in obesity drugs, including Oleoyl-estrone (OE), Manhattan Pharma's orally administered small molecule in development for the treatment of obesity. The company expects to initiate a Phase IIa study for OE in the first half of 2006.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (www.manhattanpharma.com), a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.